Disease · MONDO_0005029
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| PEGASYS vs Hydroxyurea: Number of Participants With Major Cardiovascular Events After Therapy | 1 of 82 | 1 of 86 | 168 | NCT01259856 | Trial comparisons |
| PEGASYS vs Hydroxyurea: deaths from any cause | 0 of 82 | 1 of 86 | 168 | NCT01259856 | Trial comparisons |
| PEGASYS vs Hydroxyurea: serious adverse events | 14 of 82 | 4 of 86 | 168 | NCT01259856 | Trial comparisons |
| SPD422: Safety Analysis Set vs SPD422: Post-marketing Trial Safety Analysis Set: serious adverse events | 21 of 53 | 1 of 33 | 86 | NCT01467661 | Trial comparisons |
| JAK2 Positive Participants vs JAK2 Negative Participants: serious adverse events | 0 of 23 | 0 of 24 | 47 | NCT01352585 | Trial comparisons |
| JAK2 Positive Participants vs JAK2 Negative Participants: Number of Patients With Platelet Count ≤600x10^9/L After 12 Months | 12 of 14 | 14 of 21 | 35 | NCT01352585 | Trial comparisons |
| JAK2 Positive Participants vs JAK2 Negative Participants: Number of Patients With Platelet Count ≤400x10^9/L After 12 Months | 7 of 14 | 8 of 21 | 35 | NCT01352585 | Trial comparisons |
| Agrylin (Young) vs Agrylin (Elderly): serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT00413634 | Trial comparisons |
| Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib Placebo: deaths from any cause | 0 of 5 | 0 of 6 | 11 | NCT03123588 | Trial comparisons |
| Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib PLacebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 5 of 5 | 4 of 6 | 11 | NCT03123588 | Trial comparisons |
| Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib Placebo: serious adverse events | 0 of 5 | 1 of 6 | 11 | NCT03123588 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005029/comparisons